PTC Therapeutics (PTCT) Misses Q2 EPS by 76c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results
August 4, 2022 4:01 PM EDTÂ - Total revenue of $166 million, representing 42% year-over-year growth Â
- Upstaza gene therapy granted marketing authorization by European Commission for treatment of AADC deficiency with first commercial patient treated
SOUTH PLAINFIELD, N.J., Aug. 4, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2022.Â
"We made significant progress in the second quarter toward achieving our ambitious goals for 2022. We continued to... More
